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Abstract
Childhood cancer survivors treated with hematopoietic stem cell transplantation are at high risk for pulmonary morbidity and
mortality. In this retrospective study we described transplant characteristics of pediatric patients who underwent hematopoietic
stem cell transplantation in Switzerland and how these characteristics changed over time, compared self-reported pulmonary
outcomes between transplanted and non-transplanted survivors, and investigated risk factors for the reported pulmonary
outcomes. As part of the population-based Swiss Childhood Cancer Survivor Study, we sent questionnaires to all ≥5-year
childhood cancer survivors diagnosed 1976–2010 at age ≤20 years. We included 132 transplanted survivors and 368 matched
non-transplanted survivors. During the study period transplant characteristics changed, with decreasing use of total
body irradiation and increased use of peripheral blood stem cells and mismatched and unrelated donors as transplant source.
One-fifth of transplanted survivors (20%, 95%CI 13–27%) and 18% of non-transplanted survivors (95%CI 13–21%) reported
at least one pulmonary outcome. None of the analyzed factors was significantly associated with an increased risk of pulmonary
outcomes in multivariable analysis. We found that pulmonary outcomes were frequently reported in transplanted and non-
transplanted childhood cancer survivors, indicating a strong need for long-term pulmonary follow-up care.
Introduction
Hematopoietic stem cell transplantation (HSCT) is an
effective but intensive treatment for childhood cancer.
HSCT can be performed as allogeneic or autologous
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transplantation and is used either as first line or salvage
treatment [1–4]. The history of allogeneic HSCT goes back
to the 1980 s and indications, conditioning regimens, and
donor sources have changed enormously since then [5, 6].
Pulmonary damage and late effects due to lung toxic
treatments and complications prior to, during, or after
transplantation can occur in childhood cancer survivors
(CCS) [7–9]. Lung toxic treatments include the che-
motherapeutics bleomycin, busulfan, carmustine (BCNU)
or lomustine (CCNU), radiation involving the lung tissue,
total body irradiation (TBI), and thoracic surgery [10–13].
Transplant-specific pulmonary complications include idio-
pathic pulmonary syndrome and complications from the
spectrum of pulmonary graft versus host disease (GvHD),
such as bronchiolitis obliterans or bronchiolitis obliterans
organizing pneumonia [7, 14–16]. Severe pulmonary
infections are additional complications due to long-lasting
neutropenic episodes.
Pulmonary symptoms and diseases, summarized as pul-
monary outcomes, are associated with high morbidity in
survivors [17–19]. Cohort studies showed that survivors
more often report pulmonary outcomes than siblings
[20, 21]. To date, pulmonary outcomes in survivors after
HSCT have only been reported by few single-center studies
[22, 23]. Data based on national population-based assess-
ments of pulmonary outcomes are lacking.
This nationwide retrospective study describes trans-
plant characteristics, such as transplant indications and
conditioning regimens, of pediatric patients who had
HSCT in Switzerland and how these characteristics
changed over time. Then, we compared self-reported
pulmonary outcomes between transplanted and non-
transplanted survivors and investigated risk factors for
reporting pulmonary outcomes.
Methods
The Swiss Childhood Cancer Survivor Study
The Swiss Childhood Cancer Survivor Study (SCCSS) is a
long-term national cohort study of all patients registered in
the Swiss Childhood Cancer Registry (SCCR) who have been
diagnosed since 1976, have survived ≥5 years after initial
diagnosis, and were alive at the time of study inclusion [24].
The SCCR is a nationwide, population-based cancer registry
including all patients diagnosed below age <21 years with
leukemia, lymphoma, central nervous system (CNS) tumors,
malignant solid tumors, or Langerhans cell histiocytosis [25].
From 2007 to 2017, we sent questionnaires to parents of
children aged 5–15 years, adolescents aged 16–19 years, and
adult CCS aged ≥20 years. The Ethics Committee of the
Canton of Bern approved the SCCR and SCCSS (KEK-BE:
166/2014). The SCCSS is registered at ClinicalTrials.gov
(identifier: NCT03297034).
Study population
We included all survivors who participated in the SCCSS
and had been treated in a clinic affiliated to the Swiss
Pediatric Oncology Group (SPOG) between 1976 and 2010.
As the definition of 5-year survivors was based on the year
of diagnosis and not the year of HSCT, some participants
might have been transplanted <5 years before answering the
questionnaire. As comparison group, we included survivors
participating in the SCCSS who had not had a HSCT. Non-
transplanted CCS were matched to transplanted CCS based
on sex, diagnosis, age at diagnosis (range ± 2 years), and
year of diagnosis (range ± 5 years) striving for a 1:3 ratio.
Through this matching we wanted to achieve that CCS in
both groups were as similar as possible in terms of sex, age
at diagnosis and diagnosis, but did only differ by whether
they had had HSCT or not. This matching did probably
not eliminate all other differences between the groups
since the reason for HSCT, such as high-risk status or
relapse, already demands additional treatment for the HSCT
patients.
Treatment and transplant characteristics
We collected treatment- and transplant-related character-
istics of transplanted survivors from medical records. We
calculated cumulative doses for eight known or suspected
lung toxic agents: bleomycin, busulfan, carmustin (BCNU),
cyclophosphamide, ifosfamide, lomustin (CCNU), mel-
phalan, and thiotepa [11–13, 26]. We combined cumulative
doses of alkylating agents (all chemotherapeutics except of
bleomycin) by calculating the cyclophosphamide equivalent
dose (CED) [27]. We categorized the cumulative CED as
either lower/equal to or higher than 11,300 mg/m2 with a
median-split. We converted busulfan given orally to
busulfan intravenously by multiplying it by factor 0.8 [28].
We categorized chest radiation as yes/no according to the
Children’s Oncology Group guidelines version 5.0 [13] and
included irradiation of the upper abdomen. We recorded
surgery to the thorax, lung, chest wall, mediastinum, and
thoracic spine. Needle biopsies and implantation of venous
devices were not coded as thoracic surgery. We collected
date of transplantation, history of relapse, remission status,
source of transplant, stem cell donor, cytomegalovirus
(CMV) status, sex and blood group of donor and recipient,
and information on graft versus host disease (GvHD). We
categorized stem cell transplantation into autologous and
allogeneic and further specified allogeneic transplantation
into Human Leucocyte Antigen (HLA) matched (e.g., 12/
12) and HLA-mismatched (e.g., 9/10) donors. As HLA
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typing and documentation changed substantially in the last
decades, it was not possible to assess exact HLA matching
[29, 30]. We categorized GvHD into acute and chronic
according to information from medical records.
Pulmonary outcomes
We collected information on pulmonary symptoms (chronic
cough defined as ≥3 months) and diseases (pneumonia in last
2 years, lung fibrosis, emphysema, or chest wall abnormality)
from the SCCSS questionnaires. We categorized the different
pulmonary outcomes as yes/no (present/absent) variables. In
addition to answering the questions, participants could
describe other problems as free text. Responses we could not
assign to one of the existing categories were coded as “other
pulmonary problem”. We had ≤5% missings on pulmonary
outcomes except for pneumonia (6% missings). We allocated
missing information to “not having the pulmonary outcome”
assuming that survivors would mention pulmonary outcomes
if they were clinically significant.
Clinical and lifestyle characteristics
We extracted the following clinical characteristics from the
SCCR: sex, age at diagnosis, year of diagnosis, and cancer
diagnoses according to the International Classification of
Childhood Cancer, 3rd edition [31]. For analyses, we used
the following four diagnostic categories: leukemia, where
patients with relapsed and refractory disease often receive
allogeneic HSCT, lymphoma, and neuroblastoma, where
autologous HSCT is used for relapsed or high-risk disease,
and other diagnoses, where HSCT is used less frequently.
For lifestyle characteristics we extracted smoking status
from the questionnaires (Supplementary Explanation E1).
Statistical analysis
We used descriptive statistics to describe socio-
demographic, lifestyle, and clinical characteristics of
transplanted and non-transplanted CCS. To assess trends in
transplant characteristics across transplant eras we used the
“nptrend” command in STATA software [32]. We com-
pared the prevalence of pulmonary outcomes between
transplanted and non-transplanted CCS using chi-square
tests. We used logistic regression and likelihood ratio
tests to quantify associations between sociodemographic,
lifestyle, clinical, and transplant-related variables and pul-
monary outcomes in transplanted CCS. We retained vari-
ables with a p value ≤ 0.1 in the univariable analysis for
inclusion into the multivariable model and included radio-
therapy as a priori confounder according to the literature.
We compared sociodemographic and clinical characteristics
of transplanted CCS who did or did not respond to the
questionnaire by using chi-square tests and student’s t-tests.
We used STATA software (Version 16.0, Stata Corpora-
tion, Austin, TX) to analyze the data.
Results
Characteristics of study population
We included 132 transplanted and 368 matched non-
transplanted CCS (Supplementary Figs. F1 and F2).
Transplanted responders and non-responders did not differ
in sociodemographic, lifestyle, and clinical characteristics
(Supplementary Table S1). The median age of transplanted
CCS was 6.5 years (interquartile range, IQR 2.9–11.6 years)
at cancer diagnosis and 8.8 years (IQR 4.8–13.6) at trans-
plantation. Median follow-up time was 9.8 years (IQR
7.2–15.9). Leukemia was the most frequent cancer diag-
nosis (55%), followed by lymphoma (15%), and neuro-
blastoma (14%) (Table 1).
Transplant characteristics and change over time
The absolute number of transplanted CCS who participated in
the SCCSS increased over time. Leukemia remained the most
common underlying cancer diagnosis in all three eras
(Table 2). Conditioning regimens changed with a relative but
non-significant reduction in TBI-containing regimens from
61% in the first to 39% in the other two eras (p for trend=
0.083). Among chemotherapeutics, the proportion of CCS
who received ifosfamide increased (p= 0.002) but the median
cumulative dose decreased non-significantly (p= 0.477).
Also cyclophosphamide dosage decreased (p < 0.001) with no
significant reduction in the proportion of CCS receiving it
(p= 0.186). For bleomycin there was a trend towards lower
cumulative doses in more recent eras (p= 0.094). Two-thirds
(65%) of CCS had radiotherapy involving the thorax with no
significant change over time, and 9% had thoracic surgery
with a trend to an increasing proportion of CCS in more
recent years. Nearly half of transplanted CCS received auto-
logous HSCT (46%) and in 57% HSCT was performed in
first remission or refractory disease. The proportion of trans-
planted CCS receiving peripheral blood stem cells increased
from 27% to 71% with a corresponding reduction in the
proportion of those receiving bone marrow stem cells (p for
trend <0.001). Eight CCS developed chronic GvHD (cGvHD)
but none had pulmonary GvHD (Supplementary Table S2).
Supplementary Tables S2 and S3 provide summaries of
clinical, treatment, and transplant characteristics for CCS
transplanted in autologous or allogeneic settings, stratified by
era of transplantation. Differences in CCS exposed to allo-
geneic or autologous HSCT are shown in Supplementary
Table S4.
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Prevalence of pulmonary outcomes
Any pulmonary outcome was reported as often in trans-
planted (20%) as in non-transplanted CCS (18%; p=
0.507). The occurrence of the listed pulmonary outcomes
was not significantly different between transplanted and
non-transplanted CCS. Pneumonia was the most frequently
reported outcome (Fig. 1). The proportion of transplanted
CCS reporting any pulmonary outcome did not change by
era of transplantation (Table 2).
Risk factors for pulmonary outcomes
In univariable logistic regression analysis, we found asso-
ciations between older age at cancer diagnosis (increase per
year; odds ratio [OR] 1.2, 95% confidence interval [CI]
1.05–1.28), exposure to bleomycin (OR 4.63, 95%CI
1.08–19.97), and thoracic surgery (OR 7.44, 95%CI
2.13–25.92) with any pulmonary outcome (Table 3). We
found no significant association with era of diagnosis,
treatment with other chemotherapeutics, median CED, and
thoracic radiotherapy, but numbers were small. Transplant-
related factors were also not significantly associated with
reporting of pulmonary outcomes (Table 3). In multi-
variable logistic regression analysis, the effect of thoracic
surgery was reduced to an OR of 3.91 (95%CI 0.95–16.02),
suggesting that it has been confounded by other factors
related to disease and treatment (Table 4). Most of the 12
CCS treated with thoracic surgery have been diagnosed
with Ewing sarcoma (n= 7) or lymphoma (n= 4). All
except one CCS have been transplanted autologous, most
suffered from relapsed disease (n= 10), received radio-
therapy to the chest (n= 10), were treated with open thor-
acic surgeries (n= 9), received at least one lung toxic
chemotherapeutic agent (n= 7), or have been exposed to a
combination of radiotherapy and thoracic surgery or
resection of lung tissue (n= 9) (Supplementary Table S5).
Discussion
This nationwide population-based cohort study found that
transplant characteristics changed over time with fewer
HSCT recipients receiving TBI or lung toxic chemother-
apeutics. One-fifth of ≥5-year CCS reported at least
one pulmonary outcome 10 years after cancer diagnosis
irrespective of whether they had been transplanted or not.
Our analyses point to older age at diagnosis and thoracic
surgery as possible risk factors for self-reported pulmon-
ary outcomes.
TBI is a crucial component of conditioning regimens for
allogeneic HSCT, but known to be lung toxic. Even though
TBI cannot completely be replaced by chemotherapy, such
as in acute lymphoblastic leukemia [33], we found that the
use of TBI has become less common in more recent eras.
There was a non-significant trend towards lower cumulative
doses of bleomycin and we found no evidence for a change
in cumulative doses of carmustine, but numbers were small.
The increasing use of peripheral blood stem cells in more
recent eras is in line with literature [34–36] and the
Table 1 Characteristics of transplanted (N= 132) and non-
transplanted (N= 368) childhood cancer survivors, matched by sex,
age at diagnosis, diagnosis, and year of diagnosis (1:3 ratio).
Transplanted CCS
(n= 132)
Non-transplanted
CCS (n= 368)
n (%) n (%)
Sociodemographic and lifestyle characteristics
Sex, male 69 (52) 195 (53)
Age at questionnaire,
median years (IQR)
18.4 (13.8–22.9) 18.5 (13.6–23.8)
Smoking statusa
Active smoking 7 (5) 27 (7)
Passive smoking 63 (48) 163 (44)
Former active smoking 9 (6) 20 (6)
Never smoking 54 (41) 158 (43)
Clinical characteristics
Age at diagnosis, median
years (IQR)
6.5 (2.9–11.6) 6.4 (2.7–11.4)
Age at transplantation,
median years (IQR)
8.8 (4.8–13.6) NA
Follow-up timeb, median
years (IQR)
9.8 (7.2–15.9) 10.1 (7.9–15.1)
Era of diagnosis
1976–1995 40 (30) 120 (33)
1996–2005 60 (45) 156 (42)
2006–2010 32 (25) 92 (25)
Childhood cancer diagnosis according to ICCC-3
I: Leukemia 72 (55) 214 (58)
II: Lymphoma 20 (15) 60 (16)
IV: Neuroblastoma 19 (14) 44 (12)
Otherc 21 (16) 50 (14)
CCS childhood cancer survivors, ICCC-3 International Classification
of Childhood Cancer, 3rd edition, IQR interquartile range.
a“Active” and “former active smoking” assessed in adolescents and
adults; “passive smoking” in children corresponds to having parents
who currently smoke or formerly smoked, “never smoking” in children
corresponds to having both parents who never smoked.
bTime from first diagnosis until date of answering the questionnaire.
cOther tumors in transplanted survivors include: tumors of the central
nervous system (n= 6), retinoblastoma (n= 1), malignant bone
tumors (n= 7), soft tissue sarcomas (n= 4), malignant germ cell
tumors (n= 3) Other tumors in non-transplanted survivors include:
tumors of the central nervous system (n= 12), retinoblastoma (n= 1),
malignant bone tumors (n= 9), soft tissue sarcomas (n= 4), malignant
germ cell tumors (n= 3).
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Table 2 Characteristics of transplanted childhood cancer survivors (N= 132) stratified by era of transplantation.
Total
(n= 132)
1976–1995
(n= 33)
1996–2005
(n= 51)
2006–2015
(n= 48)
p value*
n (%) n (%) n (%) n (%)
Clinical characteristics
Cancer diagnosis according to ICCC-3 0.806
I: Leukemia 72 (55) 18 (55) 26 (51) 28 (58)
II: Lymphoma 20 (15) 8 (24) 7 (14) 5 (10)
IV: Neuroblastoma 19 (14) 5 (15) 8 (16) 6 (13)
Othera 21 (16) 2 (6) 10 (19) 9 (19)
Treatment characteristics
Conditioning containing
TBI
59 (45) 20 (61) 20 (39) 19 (39) 0.083
Conditioning regimens 0.003
TBI+
cyclophosphamide
± others
34 (26) 16 (48) 12 (23) 6 (13)
TBI+ others 25 (19) 4 (12) 8 (16) 13 (27)
Busulfan +
cyclophosphamide
± other
28 (21) 7 (21) 11 (21) 10 (21)
Busulfan ± others 8 (6) 1 (3) 4 (8) 3 (6)
Carmustine ± others 9 (7) 3 (9) 3 (6) 3 (6)
Cyclophosphamide
± others
9 (7) 1 (3) 6 (12) 2 (4)
Melphalan ±
carboplatin ± others
19 (14) 1 (3) 7 (14) 11 (23)
Chemotherapeutic agents
Alkylating agents
combinedb
131 (99) 33 (100) 50 (98) 48 (100)
Busulfan 37 (28) 9 (27) 16 (31) 12 (25) 0.776
Carmustine 9 (7) 4 (12) 3 (6) 2 (4) 0.180
Cyclophosphamide 123 (93) 33 (100) 46 (90) 44 (92) 0.186
Ifosfamide 62 (47) 9 (27) 23 (45) 30 (63) 0.002
Lomustine 2 (2) 1 (3) - 1 (2) 0.835
Melphalan 44 (33) 9 (27) 17 (33) 18 (38) 0.342
Thiotepa 14 (11) 3 (9) 8 (16) 3 (6) 0.563
Bleomycin 8 (6) 3 (9) 3 (6) 2 (4) 0.371
Chemotherapeutic agents, mg/m2 (IQR)
Alkylating agents
combinedb
11329
(5687–17164)
11658
(7924–17391)
11367
(5879–21425)
8546
(4447–16131)
0.199
Busulfan 443 (324–480) 480 (470–587) 344 (297–480) 440 (374–449) 0.021
Carmustine 300 (298–300) 300 (298–351) 300 (298–300) 300 (291–306) 0.737
Cyclophosphamide 4200
(3021–7535)
7299
(4200–8684)
4247
(3090–8230)
3439
(2634–5258)
<0.001
Ifosfamide 9941
(4032–22500)
11500
(5200–16032)
10227
(4032–22500)
8181
(4017–19767)
0.477
Lomustine 395 (190–600) 190 – 600 0.317
Melphalan 140 (139–169) 140 (140–142) 140 (140–140) 140 (139–180) 0.739
Thiotepa 680 (588–900) 750 (168–900) 749 (591–900) 610 (307–900) 0.921
Bleomycin 40 (40–46) 42 (40–80) 40 (40–50) 30 (20–40) 0.094
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increasing use of mismatched (un-) related donors reflects
the overall progress in HSCT over time.
The proportion of transplanted CCS reporting any pul-
monary outcome did not change during the three HSCT
eras. Studies that compared self-reported pulmonary out-
comes in transplanted CCS are few. Fanfulla et al. exam-
ined children during the first 18 months after allogeneic
HSCT [22]. Cough was reported by 15–25% of children
and pneumonia was diagnosed in the first 6 months in 19%
of children. The occurrence of pneumonia in the first
6 months, is indicative of delayed immune reconstitution
rather than late pulmonary outcomes. Since the follow-up
(18 months) is shorter than in our population (10 years)
direct comparison is difficult. Also in the entire cohort of
Swiss CCS (N= 1 894) pneumonia was the most frequently
reported pulmonary outcome (10%), and pulmonary fibrosis
(0.8%) and emphysema (0.2%) were reported by few CCS
[20]. CCS in the North American Childhood Cancer Sur-
vivor Study showed a different distribution of pulmonary
outcomes with chronic cough being the most frequent
outcome (7.8%), followed by pulmonary fibrosis (1.9%),
and recurrent pneumonia (1.7%) [21]. We found no dif-
ference in the prevalence of pulmonary outcomes between
transplanted and non-transplanted CCS in our study (20%
vs. 18%). This could be explained by the high proportion of
leukemia (58%) and lymphoma (16%) diagnoses in non-
transplanted CCS due to the matching. A Danish cohort
study included 94 leukemia survivors a median of 10 years
from diagnosis, treated with chemotherapy only, and 11%
suffered from pulmonary problems, mainly cough [37]. A
Table 2 (continued)
Total
(n= 132)
1976–1995
(n= 33)
1996–2005
(n= 51)
2006–2015
(n= 48)
p value*
n (%) n (%) n (%) n (%)
Radiotherapy involving
the thoraxc
86 (65) 25 (76) 32 (63) 29 (60) 0.175
Thoracic surgeryd 12 (9) 1 (3) 5 (10) 6 (13) 0.157
Transplant characteristics
Remission status at transplantation 0.906
First remission 75 (57) 16 (48) 35 (69) 24 (50)
Relapsed disease 57 (43) 17 (52) 16 (31) 24 (50)
Stem cell donor 0.098
Autologous 61 (46) 17 (52) 25 (49) 19 (39)
HLA identical sibling /
HLA matched (un-)
relative donor
56 (42) 16 (48) 19 (37) 21 (44)
HLA mismatch (un-)
related /haploidentical
15 (11) 0 7 (14) 8 (17)
Source of transplant <0.001
Cord blood 6 (5) – 1 (2) 5 (10)
Peripheral blood 75 (57) 9 (27) 32 (63) 34 (71)
Bone marrow 46 (35) 22 (67) 17 (33) 7 (15)
Unknown 5 (4) 2 (6) 1 (2) 2 (4)
Pulmonary outcome 26 (20) 7 (21) 11 (22) 8 (17) 0.582
HLA human leukocyte antigen, ICCC-3 International Classification of Childhood Cancer, 3rd edition, IQR interquartile range, N number, TBI total
body irradiation.
*p value for trend.
aOther tumors include: tumors of the central nervous system (n= 6), retinoblastoma (n= 1), malignant bone tumors (n= 7), soft tissue sarcoma
(n= 4), malignant germ cell tumors (n= 3).
bCombination according to Cyclophosphamide Equivalent Dose (CED) [27].
cThoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-)
mantle field, TBI and additionally upper abdomen and thoracic spine, including craniospinal irradiation.
dThoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall surgery, rib resection, lobectomy,
pulmonary metastasectomy and wedge resection.
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US study including Hodgkin’s lymphoma survivors treated
with chest radiation but without HSCT showed that 17%
had at least one episode of pneumonia and 9% reported
dyspnea [38].
CCS who had undergone thoracic surgery in addition to
HSCT reported more pulmonary outcomes than those
without thoracic surgery. This might be because this group
of CCS had received more often thoracic radiotherapy or
lung toxic chemotherapeutics, had more often been diag-
nosed with relapsed disease, and underwent open thoracic
surgeries in most cases, which goes along with a more
intensive treatment. Residual confounding by these addi-
tional lung toxic treatment modalities probably leads to an
overestimation of the association between thoracic surgery
and pulmonary outcomes. Older age at diagnosis, resulting
in older age at HSCT, was another risk factor for pulmonary
outcomes in univariable analysis. No study has assessed
self-reported pulmonary outcomes in the context of age at
HSCT, but four studies showed an association between
older age at HSCT and deterioration in selected pulmonary
function parameters [23, 39–41]. In multivariable analysis,
bleomycin was not a risk factor for pulmonary outcomes
anymore, which is in line with findings from the whole
Swiss CCS cohort [20]. In our cohort, we found no sig-
nificant effect of other selected chemotherapeutics and
transplant-related factors on the reporting of pulmonary
outcomes. All studies that evaluated the impact of cGvHD
on the lung, used pulmonary function tests as outcome
measure [41–44]. They reported a negative effect of cGvHD
on pulmonary function. We explain the missing effect of
cGvHD, lomustine, and carmustine by the low number of
survivors exposed to each of these factors. Also some CCS
with severe pulmonary cGvHD might have died before
receiving the SCCSS questionnaire and missing or non-
detailed documentation in the medical records might have
led to an underestimation of the effect of cGvHD on pul-
monary outcomes.
We found no difference in pulmonary outcomes between
CCS treated with autologous and allogeneic HSCT. Thor-
acic surgery was overrepresented in the autologous group
because of the underlying diagnoses, mainly bone tumors.
In contrast, CCS treated with allogeneic HSCT were more
often exposed to chest radiotherapy, which can lead to
radiation pneumonitis and an increased risk of interstitial
pneumonitis due to infections such as CMV. Both factors
have not been assessed in detail.
The strengths of this study include the population-based
national design of the SCCSS, the high response rate of
transplanted CCS (71%), and the comparability between
responding and nonresponding transplanted survivors.
This makes us confident, that our results can be extra-
polated to ≥5-year Swiss survivors who underwent HSCT.
In addition, the completeness of exact treatment exposure,
including cumulative doses of chemotherapeutics and
detailed information on HSCT in transplanted CCS is
another strength.
The reliance on self-reported outcome data is a limitation
and our study did not include objective pulmonary function
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Table 3 Association between sociodemographic, clinical, treatment, and transplant characteristics on self-reported pulmonary outcomes.
Reporting of any pulmonary outcome
noutcome Ntotal % OR 95% CI p value*
Sociodemographic and lifestyle characteristics
Sex 0.795
Male 13 69 19 1
Female 13 63 21 1.12 0.47–2.64
Age at questionnaire, continuous (years) 26 132 20 1.05 0.99–1.11 0.088
Smoking statusa 0.924
Never smoking 12 60 20 1
Passive smoking 10 56 18 0.87 0.34–2.21
Former active smoking 2 9 22 1.14 0.21–6.21
Active smoking 2 7 29 1.60 0.27–9.28
Clinical characteristics
Age at diagnosis, continuous (years) 26 132 20 1.2 1.05–1.28 0.002
Follow-up time, continuous (years) 26 132 20 0.98 0.91–1.06 0.613
Era of diagnosis 0.800
1976–1990 5 20 25 1
1991–2000 8 45 18 0.64 0.18–2.31
2001–2010 13 67 19 0.72 0.22–2.35
Cancer diagnosis according to ICCC-3 0.271
Leukemia 15 72 21 1
Lymphoma 5 20 25 1.27 0.39–4.04
Neuroblastoma 1 19 5 0.21 0.03–1.71
Otherb 5 21 24 1.18 0.37–3.76
Treatment characteristics
Bleomycin 0.040
No 22 124 18 1
Yes 4 8 50 4.63 1.08–19.97
Busulfan 0.190
No 16 95 17 1
Yes 10 37 27 1.83 0.74–4.51
Nitrosureas (BCNU and CCNU) 0.107
No 22 122 18 1
Yes 4 10 40 3.03 0.79–11.65
Cyclophosphamide 0.844
No 2 9 22 1
Yes 24 123 20 0.84 0.16–4.34
Ifosfamide 0.596
No 15 70 21 1
Yes 11 62 18 0.79 0.33–1.88
Melphalan 0.281
No 15 88 17 1
Yes 11 44 25 1.62 0.67–3.91
Treosulfan 0.400
No 24 126 19 1
Yes 2 6 33 2.12 0.36–12.28
Alkylating agentsc 0.084
≤11,300 mg/m2 9 66 14 1
>11,300 mg/m2 17 66 26 2.19 0.89–5.37
Radiotherapy to chest (including TBI) 0.165
No 6 46 13 1
Yes 20 86 23 2.02 0.75–5.45
Thoracic surgery <0.001
No 19 120 16 1
Yes 7 12 58 7.44 2.13–25.92
M. Otth et al.
tests. CCS treated with open thoracic surgery are reminded
by the scar of their history and thus may be more sensitive
in dealing with their lung health, and may remember and
report pulmonary outcomes better. However, Louie et al.
reported a high agreement between self-reported pulmonary
outcomes, such as chronic cough, pulmonary fibrosis, and
emphysema, and their validation by extractions from med-
ical records (sensitivity 96.2%; specificity 90.8%) [45]. The
SCCSS has not been designed for survivors after HSCT
specifically, neither for the assessment of pulmonary out-
comes only and did not include specific questions on
exertion-induced dyspnea or effort intolerance. This might
have led to underreporting of pulmonary outcomes in
our study. Also “pneumonia” might have been misunder-
stood by lay persons, as it was not defined in the ques-
tionnaire. Survival bias due to inclusion of ≥5-year
survivors could have led to underestimation of pulmonary
outcomes as more severely affected patients might
have died. The small number of transplanted CCS who
have been exposed to specific chemotherapeutics and
transplant-related exposures did not allow for a multi-
variable analysis of all exposures in a single model. Also the
detailed information on treatment exposures, such as
cumulative doses, was only available for transplanted
CCS. Finally, the absolute numbers of CCS reporting pul-
monary outcomes was small, because the study
population was young with a relatively short follow-up
time, and the incidence of pulmonary outcomes increases
over lifetime [20, 21, 39, 46].
In summary, we found that one-fifth of CCS, including
those who underwent HSCT and matched controls, devel-
oped long-term pulmonary outcomes. As we only assessed
self-reported outcomes, using a limited number of ques-
tions, this proportion probably only represents the tip
of the iceberg. This underlines that we should implement
long-term pulmonary follow-up recommendations on a
large scale [13, 47–49] using sensitive outcome measures,
such as lung function tests, to assess the full spectrum of
long-term pulmonary sequelae after childhood cancer at an
early stage.
Table 3 (continued)
Reporting of any pulmonary outcome
noutcome Ntotal % OR 95% CI p value*
Transplant characteristics
Remission status at transplantation 0.223
First remission/primary refractory 12 75 16 1
Relapsed disease 14 57 24 1.71 0.72–4.05
Type of transplantation 0.995
Allogeneic 14 71 20 1
Autologous 12 61 20 0.99 0.42–2.35
Stem cell donor 0.739
Autologous 12 61 20 1
HLA ident. sibling, matched (un)related donor 11 56 20 0.99 0.40–2.48
HLA mismatched (un)related, haploidentical 3 15 20 1.02 0.25–4.19
Source of transplant (n= 66)d 0.933
Bone marrow 7 34 21 1
Peripheral blood 6 26 23 1.15 0.34–3.98
Cord blood 1 6 17 0.77 0.08–7.71
Graft versus host disease (n= 71)d 0.449
No 4 15 27 1
Yes 10 56 18 0.59 0.16–2.27
Results from univariable logistic regression analysis. N= 132, median age at study 18.4 years.
BCNU Lomustine, CCNU Carmustine, HLA human leukocyte antigen, ICCC-3 International Classification of Childhood Cancer, 3rd edition, OR
Odds ratio, TBI total body irradiation, CI confidence interval.
*p value calculate by logistic regression (Wald test) for continuous and binary independent variables and by likelihood ratio test for independent
variables with >2 categories.
aActive and former active smoking assessed in adolescents and adults. Passive and never smoking assessed in children, adolescent and adults.
bOther diagnostic groups include: malignant bone tumors (n= 7), tumors of the central nervous system (n= 6), soft tissue sarcomas (n= 4), germ
cell tumors (n= 3), retinoblastoma (n= 1).
cCumulative alkylating dose according to cyclophosphamide equivalent dose (CED); categorized in smaller or equal to the median or larger as the
median cumulative dose.
dIn survivors undergone allogeneic transplantation only.
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